RecruitingNot Applicable

Risk Indicators of Sarcoidosis Evolution-Unified Protocol

United States200 participantsStarted 2023-01-10

Plain-language summary

The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults with a diagnosis of sarcoidosis over the age of 18

Exclusion criteria

✕. Inability to tolerate study procedures as determined by the investigator
✕. Pregnant or breastfeeding
✕. Concurrent medical diagnoses that would influence the expression of biomarkers will be considered an exclusion criterion. This includes diseases such as common variable immunodeficiency, HIV infection, or autoimmune diseases
✕. Concurrent interstitial lung diseases such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis
✕. Hematocrit (Packed Cell Volume) \< 25%

What they're measuring

Mean Change in Forced Vital Capacity in Liters

Timeframe: Baseline and 24 months

Trial details

NCT IDNCT05567133

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2030-03-30

Contact for this trial

Laura Koth

4155144369 laura.koth@ucsf.edu

View on ClinicalTrials.gov More Sarcoidosis, Pulmonary trials